Hematologic Oncology Update Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances
Jun 18, 2025
In this enlightening discussion, Professor Meletios-Athanasios C Dimopoulos from Greece and Dr. Robert Z Orlowski from the University of Texas delve into the latest clinical advancements in multiple myeloma treatment. They explore groundbreaking therapies like tri-specific T cell engagers and belantamab's re-approval in the UK. The duo also emphasizes the significance of minimal residual disease monitoring and compares the efficacy of CAR-T therapies, shedding light on their impact on patient care and future research directions.
AI Snips
Chapters
Transcript
Episode notes
Bispecific Targeting Overcomes Antigen Variability
- Patients express multiple myeloma antigens BCMA and GPRC5D at varying levels with no direct correlation to response.
- Combining bispecifics targeting two antigens circumvents expression variability, improving efficacy and managing disease heterogeneity.
Daratumumab Delays Smoldering Progression
- Daratumumab monotherapy significantly delays progression from high-risk smoldering myeloma to symptomatic disease.
- Early intervention may become standard care pending regulatory approval, improving survival trends.
Use MRD to Guide Post-Transplant Care
- Perform minimal residual disease (MRD) testing post-transplant to guide management.
- If MRD positive, consider additional therapies to achieve MRD negativity and improve outcomes.